compound 9 [PMID: 32140747]   Click here for help

GtoPdb Ligand ID: 13566

Compound class: Synthetic organic
Comment: This small molecule is reported as an inhibitor of NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL [5], an enzyme that is essential for cholesterol synthesis. Inhibiting NSDHL is being explored as an anti-tumour mechanism [2-3], since NSDHL activity has also been implicated in epidermal growth factor receptor (EGFR) trafficking pathways [1,4]. Additional evidence supports targeting NSDHL for clinical benefit in cholesterol-related diseases.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 161.53
Molecular weight 523.56
XLogP 1.3
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=C(C=CC(=C1)C(=O)O)COC2=C(C=C(C=C2)C3=CC=C(C=C3)F)/C=C\4/C(=O)N(CC(=O)O)C(=S)S4
Isomeric SMILES OC(=O)CN1C(=S)S/C(=C\C2=C(OCC3=CC=C(C=C3)C(O)=O)C=CC(=C2)C4=CC=C(F)C=C4)/C1=O
InChI InChI=1S/C26H18FNO6S2/c27-20-8-5-16(6-9-20)18-7-10-21(34-14-15-1-3-17(4-2-15)25(32)33)19(11-18)12-22-24(31)28(13-23(29)30)26(35)36-22/h1-12H,13-14H2,(H,29,30)(H,32,33)/b22-12-
InChI Key WVGKPTIOSWSVIJ-UUYOSTAYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG et al.. (2016)
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Mol Cancer Ther, 15 (10): 2486-2497. [PMID:27507850]
2. Chen M, Zhao Y, Yang X, Zhao Y, Liu Q, Liu Y, Hou Y, Sun H, Jin W. (2021)
NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesis.
Breast Cancer Res Treat, 187 (2): 349-362. [PMID:33864166]
3. Ershov P, Kaluzhskiy L, Mezentsev Y, Yablokov E, Gnedenko O, Ivanov A. (2021)
Enzymes in the Cholesterol Synthesis Pathway: Interactomics in the Cancer Context.
Biomedicines, 9 (8). [PMID:34440098]
4. Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz LE et al.. (2015)
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR.
Cell Rep, 12 (11): 1927-38. [PMID:26344763]
5. Kim DG, Cho S, Lee KY, Cheon SH, Yoon HJ, Lee JY, Kim D, Shin KS, Koh CH, Koo JS et al.. (2021)
Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity.
Cell Mol Life Sci, 78 (1): 207-225. [PMID:32140747]